Sionna Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Sionna Therapeutics, Inc. carries a market capitalization of 181.05M, placing it among publicly traded companies globally. Its enterprise value stands at 1.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 181.05M |
| Enterprise Value | 1.78B |
Share Statistics
Sionna Therapeutics, Inc. currently has 45.16M shares outstanding.
| Shares Outstanding | 45.16M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 7.48 |
| P/TBV Ratio | 7.48 |
| P/FCF Ratio | -26.02 |
| P/OCF Ratio | -25.93 |
Financial Position
Sionna Therapeutics, Inc. maintains a current ratio of 20.05, meaning it holds 20.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 20.05 |
| Quick Ratio | 19.57 |
| Debt / Equity | 3.04 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -32.34 |
| Return on Assets (ROA) | -30.66 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Sionna Therapeutics, Inc.'s stock has declined approximately -87.54658% over the past 52 weeks. The 50-day moving average sits at 6.74, while the 200-day moving average is 31.87.
| Beta (5Y) | N/A |
| 52-Week Price Change | -87.54658% |
| 50-Day Moving Average | 6.74 |
| 200-Day Moving Average | 31.87 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -108.84M, while operating income came in at -109.49M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -109.49M |
| Pretax Income | -97.38M |
| Net Income | -97.38M |
| EBITDA | -108.84M |
| EBIT | -109.49M |
| Earnings Per Share (EPS) | -2.18 |
Balance Sheet
Sionna Therapeutics, Inc. holds 211.03M in cash and equivalents against 8.07M in total debt, resulting in a net debt position of -63.32M. Total book value stands at 265.78M, with working capital of 205.35M providing operational flexibility.
| Cash & Cash Equivalents | 211.03M |
| Total Debt | 8.07M |
| Net Debt | -63.32M |
| Equity (Book Value) | 265.78M |
| Book Value Per Share | 5.88 |
| Working Capital | 205.35M |
Cash Flow
Sionna Therapeutics, Inc. produced -75.92M in operating cash flow over the past twelve months. After subtracting -291,000.00 in capital expenditures, free cash flow totaled -76.21M - equivalent to -1.70 per share.
| Operating Cash Flow | -75.92M |
| Capital Expenditures | -291,000.00 |
| Free Cash Flow | -76.21M |
| FCF Per Share | -1.70 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.32 |
| FCF Yield | -3.84 |
Scores
Sionna Therapeutics, Inc. posts an Altman Z-Score of 66.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 66.27 |